Back to top

Image: Bigstock

Should You Get Rid of Capital Senior Living (CSU) Now?

Read MoreHide Full Article

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Capital Senior Living Corp. , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in CSU.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 1 estimate moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of 3 cents a share a month ago to its current level of a loss of 11 cents.

Also, for the current quarter, Capital Senior Living has seen 1 downward estimate revision versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 7 cents a share from earnings of 1 cent over the past 30 days.   

The stock also has seen some pretty dismal trading lately, as the share price has dropped 21.5% in the past month.

CAPITAL SR LIVG Price and Consensus
 

CAPITAL SR LIVG Price and Consensus | CAPITAL SR LIVG Quote

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical sector, you may instead consider a better-ranked stock - Anika Therapeutics Inc. (ANIK - Free Report) . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Anika Therapeutics Inc. (ANIK) - free report >>

Published in